stoxline Quote Chart Rank Option Currency Glossary
  
Vaccinex, Inc. (VCNX)
0.91  0.03 (3.41%)    07-18 16:00
Open: 0.91
High: 0.91
Volume: 135
  
Pre. Close: 0.88
Low: 0.5801
Market Cap: 2(M)
Technical analysis
2025-07-18 4:45:26 PM
Short term     
Mid term     
Targets 6-month :  0.96 1-year :  1.15
Resists First :  0.82 Second :  0.99
Pivot price 0.82
Supports First :  0.56 Second :  0.47
MAs MA(5) :  0.85 MA(20) :  0.8
MA(100) :  0.81 MA(250) :  2.31
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  47.9 D(3) :  72.1
RSI RSI(14): 36.8
52-week High :  8.89 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VCNX ] has closed below the lower bollinger band by 2.8%. Bollinger Bands are 0.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.91 - 0.92 0.92 - 0.92
Low: 0.57 - 0.58 0.58 - 0.58
Close: 0.58 - 0.58 0.58 - 0.58
Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Headline News

Fri, 07 Mar 2025
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire

Fri, 07 Mar 2025
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan

Tue, 17 Dec 2024
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com

Tue, 17 Dec 2024
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire

Tue, 17 Dec 2024
Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com

Thu, 07 Nov 2024
Vaccinex Lands Major Pharma Deals: Amgen, Merck Partner on Breakthrough Antibody Tech - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 1.18e+006 (%)
Held by Institutions 11.5 (%)
Shares Short 128 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.864e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 590.1 %
Return on Equity (ttm) -376.1 %
Qtrly Rev. Growth 601000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -8.46809e+006
Qtrly Earnings Growth -8.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.53
Stock Dividends
Dividend 0
Forward Dividend 62110
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android